drugset / Trial / NCT07619885
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
RandomizedParallel-groupOpen-labelPrevention
Summary
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.
Timeline
- Start
- 2026-06
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CG-0255 | Unknown | 0.75 mg | Intravenous |
| Comparator | Clopidogrel | Small molecule | 75 mg | Oral |